MAPK3 and esophageal squamous cell carcinoma: The CCL5-CCR5 axis inhibitor Malawijo confirmed that the removal of tumor cell-derived CCL5 diminished ERK1/2 signaling, leading to the inhibition of ESCC cell proliferation in vitro and in vivo, as well as reducing the proportion of CAFs recruited by xenograft tumors (27).